DJI46,994.77+0.94%
GDAXI23,564.01+0.50%
GSPC6,708.09+1.14%
HSI25,834.02+1.45%
IXIC22,418.06+1.41%
N22553,751.15-0.13%
AAPL252.92+1.12%
AMZN211.07+1.64%
CL93.72-5.06%
EURUSD1.1523+0.88%
GBPUSD1.3332+0.82%
GC5,004.10-1.14%
GOOG303.66+0.73%
JPM285.88+0.86%
META626.42+2.16%
MSFT399.50+1.00%
NVDA184.78+2.51%
TSLA397.93+1.72%
DJI46,994.77+0.94%
GDAXI23,564.01+0.50%
GSPC6,708.09+1.14%
HSI25,834.02+1.45%
IXIC22,418.06+1.41%
N22553,751.15-0.13%
AAPL252.92+1.12%
AMZN211.07+1.64%
CL93.72-5.06%
EURUSD1.1523+0.88%
GBPUSD1.3332+0.82%
GC5,004.10-1.14%
GOOG303.66+0.73%
JPM285.88+0.86%
META626.42+2.16%
MSFT399.50+1.00%
NVDA184.78+2.51%
TSLA397.93+1.72%
DJI46,994.77+0.94%
GDAXI23,564.01+0.50%
GSPC6,708.09+1.14%
HSI25,834.02+1.45%
IXIC22,418.06+1.41%
N22553,751.15-0.13%
AAPL252.92+1.12%
AMZN211.07+1.64%
CL93.72-5.06%
EURUSD1.1523+0.88%
GBPUSD1.3332+0.82%
GC5,004.10-1.14%
GOOG303.66+0.73%
JPM285.88+0.86%
META626.42+2.16%
MSFT399.50+1.00%
NVDA184.78+2.51%
TSLA397.93+1.72%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Bloomberg Markets EN

Hedge Fund Regal Hit by 93% Crash in Australian Biotech Stock

Sydney hedge fund Regal Partners Ltd. was dealt a fresh blow after Immutep Ltd., an Australian biotech company it backs, wiped out most of its A$582 million ($412 million) market value on Friday when it halted trials of a lung cancer drug.

Mar 13, 2026 &03531313202631; 01:53 UTC feeds.bloomberg.com Trending 3/5
Read original on feeds.bloomberg.com ↗
↘
Negative for markets
Sentiment score: -85/100
High impact Immediate effect (hours)
WHAT THIS MEANS
Sydney-based hedge fund Regal Partners suffered significant losses as its portfolio company Immutep Ltd., an Australian biotech firm, experienced a 93% market capitalization collapse following the halt of its lung cancer drug trials. This represents a major setback for the fund's investment strategy and could trigger broader portfolio adjustments.
AI CONFIDENCE
95% Very high
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↓
IMM.AX
IMM.AXStock
Expected to decline
93% market capitalization collapse due to halted lung cancer drug trials
⇅
FTSE MIB (Italy)
FTSEMIB.MIIndex
High volatility expected
Potential contagion risk from hedge fund losses affecting European financials
⇅
S&P 500
^GSPCIndex
High volatility expected
Biotech sector volatility and hedge fund redemption risk spillover
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Avoid biotech exposure in hedge fund portfolios; monitor Regal Partners for potential redemption announcements and forced asset sales. Consider hedging positions in Australian biotech indices and watch for contagion effects in other hedge fund holdings.
KEY SIGNALS
Clinical trial failure in oncology sectorMassive shareholder value destruction (A$582M market cap loss)Hedge fund concentration risk materializedPotential forced liquidations and redemption pressureBiotech sector credibility concerns
SECTORS INVOLVED
BiotechnologyHealthcareHedge Funds & Asset ManagementFinancial Services
Analysis generated on Mar 16, 2026 at 15:47 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Bloomberg Markets. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Middle East oil exports drop at least 60% as Strait of Hormuz stays mostly closed, data shows
BNN Bloomberg Mar 16, 21:13 Negative
Bell plans $1.7B AI data centre in Saskatchewan as demand for computing power surges
BNN Bloomberg Mar 16, 21:03 Positive
Urbana Corporation Intersects 4.2 g/t Au over 10 Metres and Begins Second Drill Program
BNN Bloomberg Mar 16, 20:59 Positive
Surging gas prices threaten to reverse Canada’s inflation progress, economists say
BNN Bloomberg Mar 16, 20:46 Negative
Market Outlook: Iran conflict and oil surge raise stakes before U.S. Fed
BNN Bloomberg Mar 16, 20:43 Negative